Toggle light / dark theme

Lab-grown pineal gland organoids produce melatonin, offering a new sleep model

Organoids are miniature, simplified versions of an organ. Over the past two decades, scientists have developed them for the gut, lung, liver, mammary gland, brain, and more. Now, researchers at Yale School of Medicine (YSM) have organoid-ized the pineal gland, a small structure in the brain that regulates sleep patterns through its production of the hormone melatonin.

In a study published in Cell Stem Cell, the researchers demonstrate how pineal gland organoids can be used to study sleep dysfunction in conditions like Angelman syndrome, autism, and depression.

“In a number of neuropsychiatric conditions, severe sleep problems are a major symptom,” says In-Hyun Park, Ph.D., associate professor of genetics at YSM and senior author of the study. “With pineal gland organoids, we may be able to uncover the causes of those sleep disturbances and possibly identify treatments.”

Little-used cholesterol test could prevent more heart attacks and strokes

A routine blood test taken by millions in the U.S. each year to measure “bad” cholesterol is not the best measure to guide treatment and prevent heart attacks and strokes, suggests a new Northwestern Medicine study published in JAMA. The study found that another blood test called apolipoprotein B (apoB) outperformed LDL and non-HDL cholesterol in guiding cholesterol-lowering therapy, such as taking statins and other medications.

“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. health care payers,” said study lead author Ciaran Kohli-Lynch, assistant professor of preventive medicine in the division of epidemiology at Northwestern University Feinberg School of Medicine.

According to Kohli-Lynch, this is the first comprehensive study to show that using apoB testing to guide cholesterol-lowering treatment is cost-effective.

Double‐Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration

A novel synergistic drug combination (N + A) consisting of an NAD+ precursor (NMN) and an NAD+ consumption (CD38) inhibitor (API) promotes musculoskeletal regeneration in aging. Notably, increased NAD+ serves as a coenzyme for SIRT3, exerting a robust anti-senescence effect, thus promoting tri-lineage differentiation into chondrocytes, osteoblasts, and myocytes. Furthermore, oral administration of the N + A formulation modulated the intestinal microenvironment, promoting the gut microbiota-derived production of the metabolite PHS, thereby exerting indirect anti-aging effects in musculoskeletal disorders.

A ‘stemness checkpoint’ helps control stem cell identity

A study published in Cell Research advances a central idea in stem cell biology by identifying a checkpoint that controls the identity of many different types of stem cells across developmental stages. For nearly two decades, scientists have understood that stem cell self-renewal depends on blocking differentiation signals—a concept described in earlier work, including Qi-Long Ying and Austin Smith’s 2008 Nature paper titled “The ground state of embryonic stem cell self-renewal.”

Now, researchers from the labs of Ying at USC and Guang Hu at the National Institute of Environmental Health Sciences (NIEHS), one of the National Institutes of Health (NIH), have identified the protein GSK3α as a “stemness checkpoint” that drives differentiation and that can be inhibited to maintain stem cell identity.

This discovery introduces a new conceptual framework: Rather than viewing stem cell maintenance as the result of many unrelated signaling conditions, distinct stem cell types share common checkpoints.

Sound-sensing hair bundles in our ears act as tiny thermodynamic machines

The hair cells lining the inner ear are among the most sophisticated structures in the human body: capable of detecting sounds as faint as a whisper, while helping to maintain our sense of balance. Through new models detailed in PRX Life, a team led by Roman Belousov at the European Molecular Biology Laboratory has revealed for the first time how oscillating bundles attached to these cells operate in different thermodynamic regimes—offering a new framework for understanding how our hearing works at a fundamental level.

Within the inner ear, each hair cell hosts a hair “bundle”: a cluster of tiny, bristle-like projections that vibrate in response to incoming sound waves. The mechanical energy from these oscillations is then converted into electrical signals which travel to the brain. Rather than being passive receivers, these bundles actively oscillate —driven by molecular motors within the cell that allow them to amplify faint signals and tune in to specific frequencies.

But despite decades of study, researchers are still unclear on the connection between this active oscillation and the hair bundle’s response to external sound. Existing models tended to treat bundles as if they were moving spontaneously, without accounting for what happens when they actually interact with sound.

AI uncovers hidden immune defenses inside bacteria

Researchers at the Massachusetts Institute of Technology (MIT) have discovered thousands of new proteins that protect bacteria from virus attacks using an AI system called DefensePredictor. What would usually take months of lab work can now be narrowed down to promising candidates in minutes.

Bacteria are under constant attack from viruses called bacteriophages. One of their most powerful defenses is CRISPR-Cas, a system that cuts up viral DNA to stop an infection and is now a valuable biotechnology tool for precisely editing genes in a lab.

Traditional methods of finding these defenses are long and laborious, equivalent to looking for a needle in a haystack. They involve searching for nearby known defensive genes and manually testing thousands of DNA fragments. But now, AI can take the strain.

Key protein found to protect cartilage, offering new hope for osteoarthritis treatment

Osteoarthritis, a condition that causes pain and reduced mobility in joints such as the knees and fingers, is one of the most common joint disorders worldwide, particularly among aging populations. The disease is characterized by the gradual breakdown of cartilage, which normally cushions the bones within joints.

Despite its prevalence, current treatments for osteoarthritis mainly focus on alleviating pain rather than addressing the underlying cause of cartilage degeneration. Effective therapies that can halt or reverse cartilage damage remain limited.

A joint research team led by Dr. Chul-Ho Lee and Dr. Yong-Hoon Kim at the Laboratory Animal Resource Center of the Korea Research Institute of Bioscience and Biotechnology (KRIBB), in collaboration with Prof. JinHyun Kim at Chungnam National University Hospital, has identified a key protein, SHP (NR0B2), that plays a critical protective role in cartilage and may offer a new therapeutic strategy for osteoarthritis. The paper is published in the journal Nature Communications.

DNA polymerase μ protects macrophages from DNA damage produced during pro-inflammatory activation

Polμ is induced in macrophages by ROS upon pro-inflammatory stimuli and is essential for efficient repair of DNA double-strand breaks. Its deficiency compromises macrophage survival and persistence in inflammatory models of infection and tissue repair, underscoring Polμ’s critical role in counteracting ROS-mediated genotoxic stress and in achieving a correct inflammatory resolution.

Metabolic dysfunction-associated steatotic liver disease and steatohepatitis-associated hepatocarcinoma preclinical models

Preclinical models are essential to study disease pathogenesis and test novel treatments. Here, a broad overview ofis provided, detailing main features, advances and limitations of in vitro and in vivo models, and how they translate to human disease.

Mapping mutations at scale in a single gene reveals new neurodevelopmental condition

The ability of different genetic variants—changes to one or more building blocks of DNA—to cause disease, and to what extent, has historically been opaque. Geneticist and Crick group leader Greg Findlay has pioneered a new method in the hope of changing this. Called “saturation genome editing,” the new technique involves mapping every single variant in a given gene to work out what it does and pinpoint which changes are responsible for specific disorders.

While Greg was refining these experiments, Nicky Whiffin, associate professor at the University of Oxford, had identified that mutations in a tiny gene were behind a rare inherited neurodevelopmental disorder, known as ReNU syndrome, which impacts brain function, development and motor skills. Children develop this syndrome if a single copy of the RNU4-2 gene is mutated in a specific way.

Nicky initially found that several distinct mutations in a critical region of the gene caused the condition, and she was keen to understand if some of these genetic variants led to more severe disease.

/* */